Health & Fitness
Mon, November 1, 2010Sat, October 30, 2010Fri, October 29, 2010Thu, October 28, 2010Wed, October 27, 2010Tue, October 26, 2010Mon, October 25, 2010Sun, October 24, 2010Sat, October 23, 2010Fri, October 22, 2010Thu, October 21, 2010Wed, October 20, 2010Tue, October 19, 2010Mon, October 18, 2010Sun, October 17, 2010Sat, October 16, 2010Fri, October 15, 2010Thu, October 14, 2010Wed, October 13, 2010Tue, October 12, 2010Obagi Medical Products to Report Third Quarter 2010 Financial Results and Host a Conference Call on November 4
Published in Health and Fitness on Thursday, October 21st 2010 at 13:15 GMT by Market Wire
LONG BEACH, Calif.--([ BUSINESS WIRE ])--Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced that its third quarter 2010 financial results will be released after the market close on Thursday, November 4, and will be followed by an investor conference call on the same day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Investors interested in participating in the live call can dial 877-407-9039 from the U.S. International callers can dial 201-689-8470. A telephone replay will be available approximately two hours after the call concludes through Thursday, November 18, by dialing 877-870-5176 from the U.S., or 858-384-5517 for international callers, and entering replay pin # 359440.
There also will be a simultaneous webcast available on the Investor Relations section of the Company's web site at [ www.obagi.com ]. For those unable to participate during the live broadcast, the webcast will be archived for 30 days.
About Obagi Medical Products, Inc.
Obagi Medical Products is a specialty pharmaceutical company that develops, markets and sells, and is a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. Using its Penetrating Therapeutics technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier to treat the most common and visible skin conditions in adults including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. The history of Obagi Medical's skin care product introductions is as follows: Obagi Nu-Derm®, 1988; Obagi-C® Rx (the first prescription-strength vitamin C and hydroquinone system), 2004; Obagi® Professional-C (a line of highly stable vitamin C serums), 2005; Obagi Condition & Enhance® for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm® eye treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, 2007; Obagi ELASTIderm® D©colletage System, 2008; the Obagi Rosaclear® System for rosacea, 2009; Refissaa" Tretinoin Emollient Cream, 0.05%, 2009 and ELASTILasha" in 2010. Visit [ www.obagi.com ] for more information.
